The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | Immune checkpoint inhibitors and their role in MM: pembrolizumab and durvalumab
Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamenca, Salamenca, Spain, talks to us about the role of immune checkpoint inhibitors in the treatment of multiple myeloma (MM). The anti-PD1/PD-L1 monoclonal antibody, pembrolizumab, and the anti-PD-L1 drug, durvalumab, have been shown to have acceptable safety profiles and effectiveness in clinical trials evaluating their clinical benefit in treating MM and their results have been presented at the ASCO congress. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
